José van den Berg
By using WGS, we took a step forward in molecular diagnostics in our department from the analysis of less than 100 genes to approximately 20,000 genes per patient. This provides an enormous amount of valuable information, not only for the patient of today, but also for the patient of the future.
Back to newsMore news
New CPoC grant awarded: GLOW – GLioblastoma targeted treatment Option maximisation by WGS
Oncode Institute has announced that the 13th grant within the Clinical Proof of Concept programme has been awarded. Oncode Investigator …
Patients can benefit from whole genome sequencing for immunotherapy
Immunotherapy is an effective treatment for many people with cancer. The number of abnormalities in the DNA of the tumor in …
Clinical Cancer Genomics 2025: a cheerful boost for this rapidly emerging field
The atmosphere is buzzing, the excitement is almost tangible. This first Clinical Cancer Genomics Congress feels like an event that …
Just one WGS test is enough to reveal everything you need to know to provide a patient with metastatic cancer with targeted treatment, be it a registered therapy or part of a research trial.